Similarly, targeting CCL5, an IL-1ß target, in breast cancer with anti-CCL5 antibodies has been described to decrease the immunosuppressive activity of MDSCs and reduce tumor metastasis [43]. This evidence concerns the gene IL1B and neoplasm.